Shining a (Red) Light on Myopia - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Shining a (Red) Light on Myopia

Repeated low-level-red-light therapy – a powerful new approach to myopia management

  • By

  • Julian Upton

  • November 25, 2023

  • 4 min

Share

Objective:

To address the growing crisis of childhood myopia and present a non-invasive treatment option.

Approach:
  • Device Development: Eyerising International developed a Myopia Management Device that uses repeated low-level red-light therapy (RLRL) for home use.
  • Clinical Trials: Clinical trials demonstrated significant reductions in myopia progression among children using the RLRL device.
Key Findings:
  • Children in the RLRL-plus-spectacles group had a 76.6% reduction in myopia progression compared to the spectacles-only group.
  • Children with high compliance (>75%) experienced an 87.7% reduction in myopia progression.
  • Continued RLRL therapy resulted in a 75% reduction in myopia progression over 12 months.
Interpretation:

Limitations:
  • The long-term effects of RLRL therapy beyond the trial period are not fully established.
  • The device's efficacy may vary based on individual compliance and other factors.
Conclusion:

Sources:

Original Source(s)

Shining a (Red) Light on Myopia

  • by Julian Upton

  • November 25, 2023

Related Content

Glycemic variability may signal retinal changes

Greater glucose fluctuations but not HbA1c were associated with neuroretinal alterations over 3 years in pediatric patients with type 1 diabetes.

Parents’ perception of common childhood eye diseases: a community-based cross-sectional study

Microsporidial keratoconjunctivitis may mimic allergy

Molecular testing identified Encephalitozoon hellem in a 9-year-old orthokeratology lens wearer after conventional treatment failed.